Results 51 to 60 of about 12,232 (185)

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review

Therapeutic Advances in Drug Safety, 2021
Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or “statins,” which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United
Wei C. Yuet, Didi Ebert, Michael Jann
doaj   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Application of PCSK9 Inhibitors in Practice [PDF]

Circulation Research, 2017
Although the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering.
Tina M, Kaufman, P Barton, Duell, Jonathan Q, Purnell, Cezary, Wójcik, Sergio, Fazio, Michael D, Shapiro   +5 more
openaire   +2 more sources

Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression

Cell Proliferation, EarlyView.
PCSK9 aggravates AAA by promoting ferroptosis in VSMCs. In the pathological AAA environment, PCSK9 upregulation triggers ferritinophagy‐dependent degradation of FTH1, leading to Fe2+ release, triggering lipid peroxidation and ferroptosis, exacerbating AAA.
Mengdie Xia, Man Li, Yanyu Chen, Jialin Chen, Yuting Cui, Xi‐Long Zheng, Jing Yang, Bingzhao Li, Xiaofeng Ma, Miao Liu, Gang Fan, Juan Peng, Xiaoyan Dai, Zhihan Tang   +13 more
wiley   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, EarlyView.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study

Frontiers in Pharmacology
BackgroundPCSK9 inhibitors are a novel class of lipid-lowering medications, and numerous clinical studies have confirmed their significant role in improving the progression of chronic kidney disease.
Hailing Liu
doaj   +1 more source

PCSK9 inhibitors in the prevention of cardiovascular disease [PDF]

Journal of Thrombosis and Thrombolysis, 2016
Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) remains the cornerstone in the primary and secondary prevention of cardiovascular disease. However, lack of efficacy and adverse effects mean that a substantial proportion of patients fail to achieve acceptable LDL-C levels with currently available lipid-lowering drugs. Over the last
Latimer, James, Batty, Jonathan A., Neely, R. Dermot G., Kunadian, Vijay   +3 more
openaire   +2 more sources

FURIN induces vascular endothelial cell death and efferocytosis through enzymatic cleavage of thrombospondin‐1

The Journal of Physiology, EarlyView.
Abstract figure legend FURIN induces vascular endothelial cell (VEC) death and efferocytosis through enzymatic cleavage of thrombospondin‐1 (THBS1). FURIN interacts with THBS1 to induce VEC apoptosis and efferocytosis, resulting in increased endothelial permeability.
Runji Chen, Daifei Shen, Amandine Mahieux, Dedrick Song, Shiwan Wu, Xiaoxin Huang, Xu Yang, Kunwei Chen, David G. McVey, Elisa A. Liehn, Roshni R. Singaraja, Shu Ye   +11 more
wiley   +1 more source